Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer.
Masuda T, Hirata T, Sakamoto T, Tsubata Y, Ichihara E, Kozuki T, Shoda H, Motonaga M, Yoshida T, Fukutani M, Tsuji-Takayama K, Tamura A, Amagase H, Fujihara H, Aoki G, Akita T, Orihashi Y, Miyata T, Hattori N. Masuda T, et al. Among authors: miyata t. J Thorac Dis. 2024 May 31;16(5):3381-3388. doi: 10.21037/jtd-23-1858. Epub 2024 May 27. J Thorac Dis. 2024. PMID: 38883673 Free PMC article.
Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol.
Fujimura T, Yoshino K, Nakamura M, Kato H, Ito T, Maekawa T, Fujisawa Y, Matsushita S, Amagai R, Yamazaki E, Takahashi M, Tamabuchi E, Hashimoto A, Kambayashi Y, Yamazaki N, Miyata T, Asano Y. Fujimura T, et al. Among authors: miyata t. Exp Dermatol. 2024 Jan;33(1):e14976. doi: 10.1111/exd.14976. Epub 2023 Nov 9. Exp Dermatol. 2024. PMID: 37946551
A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial.
Fujimura T, Yoshino K, Kato H, Fukushima S, Ishizuki S, Otsuka A, Matsushita S, Amagai R, Muto Y, Yamazaki E, Kambayashi Y, Yahata T, Miyata T, Fujisawa Y, Asano Y. Fujimura T, et al. Among authors: miyata t. Br J Dermatol. 2024 Oct 17;191(5):691-697. doi: 10.1093/bjd/ljae231. Br J Dermatol. 2024. PMID: 38833158 Clinical Trial.
A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19.
Hirai T, Asano K, Ito I, Miyazaki Y, Sugiura H, Agirbasli M, Kobayashi S, Kobayashi M, Shimada D, Natsume I, Kawasaki T, Ohba T, Tajiri S, Sakamaki F, Mineshita M, Takihara T, Sekiya K, Tomii K, Tomioka H, Kita H, Nishizaka Y, Fukui M, Miyata T, Harigae H. Hirai T, et al. Among authors: miyata t. Sci Rep. 2024 Jan 2;14(1):165. doi: 10.1038/s41598-023-50445-1. Sci Rep. 2024. PMID: 38168544 Free PMC article. Clinical Trial.
[Drug discovery and development in academia].
Miyata T. Miyata T. Rinsho Shinkeigaku. 2011 Nov;51(11):1084. doi: 10.5692/clinicalneurol.51.1084. Rinsho Shinkeigaku. 2011. PMID: 22277487 Japanese. No abstract available.
2,221 results